What Growth Plank Will The Phenylketonuria Treatment Market Move To In The Next 10 Years?
Phenylketonuria (PKU) is an inherited disorder caused by excess of phenylalanine in the blood, which can lead to severe intellectual disabilities. There is no cure for phenylketonuria as yet, and dietary management is the only option to maintain the phenylalanine level in the body. Untreated infants with PKU tend to have unusually light eye, skin, and hair colour due to excess of phenylalanine levels interfering with melanin. Neurological symptoms such as seizures, abnormal muscle movement, tremors, or involuntary movement are some of the symptoms mainly observed in such patients.
Rising prevalence of phenylketonuria among newborns and surging demand for novel formulations to treat the disease have led to increased opportunities for market players. Stakeholders are investing more in research & development for novel treatment solutions within the nutraceutical industry.
Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/14410
Companies covered in Phenylketonuria Treatment Market Report
Arla Foods Ingredients Group P/S
Archer Daniels Midland Company
Seidler Chemical Co, Inc.
Nestlé S.A. (Vitaflo International)
Reckitt Benckiser Group plc. (Mead Johnson & Company, LLC.)
APR Applied Pharma Research S. A.
Ajinomoto Co., Inc.
Pristine Organics Pvt. Ltd
Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/14410
According to the latest report published by Persistence Market Research, the global phenylketonuria treatment market for protein ingredients was valued at US$ 325.9 Mn in 2019, and is predicted to witness an impressive CAGR of over 6% during the forecast period (2020–2030). Similarly, the market for finished products was valued at US$ 565.8 Mn in 2019, and is predicted to witness an impressive CAGR of around 7% through 2030.
Key Takeaways from Phenylketonuria Treatment Market Study
For Protein Ingredients
Essential and non-essential amino acid ingredients are expected to contribute more than 1/3 of the revenue share in the market.
Powder blend form is expected to gain traction in phenylketonuria treatment, accounting for more than 90% share throughout the forecast years.
By targeted customer, consumer healthcare companies hold the highest share of more than 80% in this space.
By sales channel, industry sales of protein ingredients are dominating the market.
North America holds the highest share in the global phenylketonuria treatment market, owing to the presence of big market players and growing research & development efforts in the region.
Key players are focused on expanding their product portfolios and expansion at regional levels through collaborations and acquisitions.
The market in the U.S. is projected to be the fastest-growing at a CAGR above 6.5% through 2030. The U.S. holds a big portion of the market revenue and accounts for more than 90% in North America.
For Finish Products
Essential and non-essential amino acids are expected to contribute more than 1/3 of the revenue share in the market.
The powder & granules form is expected to dominate phenylketonuria treatment, accounting for a share of more than 50% through 2030.
By targeted customer, adults account for the highest market share of more than 50%.
By sales channel, hypermarkets and supermarkets will hold the highest share throughout the forecast period.
North America holds more than 40% of the global phenylketonuria treatment market share.
Key market players are focusing on expansion of their product portfolios by highly investing in the research & development sector, and are generating high revenue through collaborations and acquisitions.
The market in the U.S. is projected to be the fastest-growing, and will expand at a CAGR close to 6% through 2030. The U.S. holds a big portion of the market revenue, and accounts for more than 90% share in North America.
“Increasing prevalence of PKU and rising adoption of PKU diets will...
Do you already have an account? Log in here